licogliflozin (LIK066) / Novartis 
Welcome,         Profile    Billing    Logout  
 5 Diseases   1 Trial   1 Trial   89 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
licogliflozin (LIK066) / Novartis
2017-001373-16: Study of LIK066 in overweight and obese women with polycystic ovary syndrome

Not yet recruiting
2
24
Europe
LIK066 50 mg, LIK066, Film-coated tablet
Novartis Pharma AG, Novartis Pharma AG
polycystic ovary syndrome, polycystic ovary syndrome, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
ELIVATE, NCT04065841 / 2019-002324-32: Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

Terminated
2
234
Europe, Canada, Japan, US, RoW
Tropifexor, LJN452, Licogliflozin, LIK066, Placebo
Novartis Pharmaceuticals
Non Alcoholic Steatohepatitis (NASH)
10/22
10/22

Download Options